Format

Send to

Choose Destination
Lung Cancer. 2015 Dec;90(3):617-9. doi: 10.1016/j.lungcan.2015.10.025. Epub 2015 Oct 29.

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

Author information

1
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA; Sydney Medical School, University of Sydney, Sydney, Australia.
2
Sydney Medical School, University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia.
3
Sydney Medical School, University of Sydney, Sydney, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
4
Sydney Medical School, University of Sydney, Sydney, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia; School of Medicine, University of Western Sydney, NSW, Australia.
5
Sydney Medical School, University of Sydney, Sydney, Australia; Department of Medical Genomics, Royal Prince Alfred Hospital, Sydney, Australia.
6
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA.
7
Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
8
Sydney Medical School, University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia. Electronic address: nick.pavlakis@sydney.edu.au.

Abstract

Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.

KEYWORDS:

Afatinib; Human epidermal growth factor receptor 2 (HER2); Lung cancer; Mutation; Targeted therapy

PMID:
26559459
PMCID:
PMC4724317
DOI:
10.1016/j.lungcan.2015.10.025
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center